Which of the following procedures is associated with the maximum chance of re-canalization during surgery for reversal of tubal ligation?
A couple presents to a clinic for the work-up of infertility after 5 years of unprotected intercourse. The wife denies any medical problems and notes regular menstrual cycles. The husband reports a history of chronic sinusitis and lower respiratory tract infections. Physical examination of the woman is unremarkable. Examination of the man reveals dextrocardia. Further work-up of the husband will most likely reveal?
What is the initial starting dose of clomiphene citrate for infertility?
Treatment with clomiphene citrate should be limited to how many ovulatory cycles?
Fallopian tube dysmotility is seen in which of the following conditions?
Considering the demands of modern life schedules, what is the accepted minimum period of unprotected sexual cohabitation for a couple to be considered infertile?
Which of the following is NOT an essential criterion according to WHO for normal semen analysis?
A woman treated for infertility presents with 6 weeks of amenorrhea and urinary retention. What is the most likely etiology?
In long protocol In Vitro Fertilization (IVF), on which day is GnRH agonist typically started?
What is the recommended treatment for a patient with infertility and an 8 cm endometriotic cyst?
Explanation: **Explanation:** The success of tubal re-anastomosis (reversal of tubal ligation) depends primarily on the **luminal diameter match** and the total remaining length of the fallopian tube. **Why Isthmic-isthmic anastomosis is correct:** The **isthmus** is the narrowest part of the fallopian tube with a thick muscular wall and a uniform, small luminal diameter. When both ends of the segment to be joined are isthmic, there is a **perfect luminal match**. This anatomical symmetry allows for precise microsurgical suturing, leading to the highest patency rates (up to 80-85%) and the highest subsequent pregnancy rates. **Analysis of Incorrect Options:** * **Isthmic-ampullary anastomosis:** This involves a "size mismatch" because the isthmic lumen is narrow while the ampullary lumen is significantly wider and more mucosal. This discrepancy makes the surgical joining more technically challenging and slightly less successful than a pure isthmic-isthmic repair. * **Ampullary-ampullary anastomosis:** While the diameters match, the ampulla has a very thin muscularis and a complex mucosal fold system. This makes it difficult to achieve stable approximation without compromising the delicate endosalpinx, leading to lower success rates compared to the isthmus. * **Cornual obstruction:** This refers to a site of blockage rather than a type of anastomosis. Reversal involving the cornua (tubo-cornual anastomosis) is technically the most difficult and carries a higher risk of failure compared to mid-tubal repairs. **NEET-PG High-Yield Pearls:** * **Best Prognostic Factor:** The most important factor for success is the **total length of the reconstructed tube** (>4 cm is ideal; <3 cm has a poor prognosis). * **Method of Ligation:** Reversal is most successful after **mechanical occlusion** (clips or rings) because they destroy the least amount of tissue compared to cautery. * **Ectopic Risk:** Patients must be counseled that tubal surgery increases the risk of future ectopic pregnancy. * **Gold Standard:** Microsurgical tubal re-anastomosis is the traditional gold standard, though IVF is now a common alternative.
Explanation: ### Explanation The clinical presentation describes a classic case of **Kartagener Syndrome**, a subset of **Primary Ciliary Dyskinesia (PCD)**. This autosomal recessive disorder is characterized by the triad of **situs inversus** (indicated by dextrocardia), **chronic sinusitis**, and **bronchiectasis** (recurrent lower respiratory infections). **1. Why "Immotile sperm" is correct:** The underlying defect in Kartagener Syndrome is a structural abnormality in the **dynein arms** of cilia and flagella. Since the tail of a spermatozoon is a modified flagellum, the defect renders the sperm structurally intact but functionally **immotile** (Asthenozoospermia). While the sperm count is usually normal, they cannot swim to fertilize the oocyte, leading to infertility. **2. Why the other options are incorrect:** * **Azoospermia:** This refers to the absence of sperm in the ejaculate. In Kartagener syndrome, sperm production is normal; the issue is motility, not absence. Azoospermia is more characteristic of Cystic Fibrosis (due to Congenital Bilateral Absence of Vas Deferens - CBAVD). * **Germinal cell aplasia (Sertoli Cell Only Syndrome):** This involves the absence of germ cells in the seminiferous tubules, leading to azoospermia. It is not associated with ciliary defects or situs inversus. * **Isolated gonadotropin deficiency (Kallmann Syndrome):** This presents with hypogonadotropic hypogonadism and anosmia. It would result in low sperm counts and low testosterone, which does not fit the respiratory symptoms or dextrocardia. **Clinical Pearls for NEET-PG:** * **Kartagener Triad:** Situs inversus, Bronchiectasis, Sinusitis. * **Diagnostic Test:** Electron microscopy of ciliary biopsy (showing absent dynein arms) or nasal nitric oxide levels (low in PCD). * **Fertility Management:** Since the sperm are viable but immotile, **Intracytoplasmic Sperm Injection (ICSI)** is the treatment of choice for these patients. * **Cystic Fibrosis vs. Kartagener:** Both have respiratory issues, but CF presents with **Azoospermia** (obstructive), while Kartagener presents with **Immotile sperm**.
Explanation: **Explanation:** **Clomiphene Citrate (CC)** is the traditional first-line pharmacological agent for ovulation induction, particularly in women with WHO Group II ovulatory dysfunction (e.g., Polycystic Ovary Syndrome). **Why 50 mg/day is correct:** The standard protocol for Clomiphene Citrate initiation is a starting dose of **50 mg per day for 5 consecutive days**, typically beginning on Day 2, 3, 4, or 5 of the menstrual cycle. This dose is chosen because it is the lowest effective dose that achieves ovulation in approximately 50% of patients while minimizing the risk of side effects like multiple pregnancies and Ovarian Hyperstimulation Syndrome (OHSS). If ovulation is not achieved at 50 mg, the dose is increased in subsequent cycles in increments of 50 mg (up to a maximum of 150 mg). **Why other options are incorrect:** * **30 mg, 40 mg, and 60 mg/day:** These are not standard manufactured strengths or recommended starting doses. Clomiphene is commercially available in **50 mg tablets**. Starting at doses lower than 50 mg is generally sub-therapeutic, and starting higher increases the risk of anti-estrogenic effects on the endometrium and cervical mucus. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** It is a **Selective Estrogen Receptor Modulator (SERM)**. It acts as a competitive antagonist to estrogen receptors in the hypothalamus, blocking negative feedback. This leads to increased GnRH secretion, which stimulates the pituitary to release more **FSH and LH**, promoting follicular growth. * **Success Rates:** Ovulation occurs in ~70-80% of cases, but the pregnancy rate is lower (~30-40%) due to its anti-estrogenic effect on the endometrium. * **Side Effects:** Most common is **vasomotor flushes** (hot flashes). The most serious is **OHSS** (though less common than with gonadotropins). * **Multiple Pregnancy:** There is a 5-10% risk, predominantly twins.
Explanation: **Explanation:** **Clomiphene Citrate (CC)** is a Selective Estrogen Receptor Modulator (SERM) and the traditional first-line agent for ovulation induction in WHO Group II anovulation (e.g., PCOS). **Why 6 cycles?** The correct answer is **6 cycles** because clinical data shows that approximately **75-80% of pregnancies** occurring with CC treatment happen within the first six ovulatory cycles. Continuing treatment beyond this point offers a significantly diminishing return on the pregnancy rate. Furthermore, prolonged use (typically defined as >12 cycles) has been historically linked to a theoretical increased risk of borderline ovarian tumors, though the primary reason for the 6-cycle limit is **clinical futility**. If a patient has not conceived after 6 ovulatory cycles, they are classified as "clomiphene failures," and the treatment strategy should be escalated to gonadotropins or IVF. **Analysis of Incorrect Options:** * **A (3 cycles):** While some clinicians evaluate progress early, 3 cycles are insufficient to declare treatment failure, as many patients conceive between cycles 3 and 6. * **C & D (10 & 12 cycles):** Continuing CC for 10-12 cycles is avoided due to the lack of additional efficacy and the potential anti-estrogenic effects of CC on the cervical mucus and endometrium, which may actually hinder implantation over time. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Blocks estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing endogenous **GnRH, FSH, and LH** pulses. * **Dosage:** Usually started at **50 mg/day** for 5 days (Day 2-6 or 3-7 of the cycle). Max dose is 150 mg. * **Side Effects:** Multiple pregnancies (approx. 8-10%, mostly twins), hot flashes, and Ovarian Hyperstimulation Syndrome (OHSS - though less common than with gonadotropins). * **Monitoring:** Ovulation is typically expected 5–10 days after the last pill.
Explanation: **Explanation:** **Correct Answer: C. Kartagener syndrome** **Mechanism:** Kartagener syndrome is a subset of **Primary Ciliary Dyskinesia (PCD)**, characterized by the triad of situs inversus, chronic sinusitis, and bronchiectasis. The underlying pathology is a genetic defect in the **dynein arms** of cilia (9+2 microtubule arrangement). In the female reproductive tract, the internal surface of the Fallopian tubes is lined with ciliated columnar epithelium. These cilia are responsible for the rhythmic transport of the ovum toward the uterus and assisting sperm motility. In Kartagener syndrome, these cilia are dysfunctional or immotile, leading to **tubal dysmotility**. This results in an increased risk of subfertility and ectopic pregnancy. **Analysis of Incorrect Options:** * **A. Noonan Syndrome:** An autosomal dominant disorder (often PTPN11 mutation) characterized by short stature, webbed neck, and pulmonary stenosis. It does not affect ciliary function. * **B. Turner Syndrome (45, XO):** The primary cause of infertility here is **gonadal dysgenesis** (streak ovaries) leading to premature ovarian failure, not tubal dysmotility. * **D. Marfan Syndrome:** A connective tissue disorder caused by FBN1 mutations affecting fibrillin-1. While it can lead to uterine organ prolapse due to tissue laxity, it does not involve ciliary dysfunction. **NEET-PG High-Yield Pearls:** * **Male Infertility in Kartagener:** Caused by immotile spermatozoa (the sperm tail is a modified flagellum with the same dynein structure). * **Ectopic Pregnancy:** Tubal dysmotility is a major risk factor for tubal ectopic gestation because the embryo is not transported to the uterine cavity in time. * **Diagnosis:** Screening is done via nasal Nitric Oxide levels; definitive diagnosis is via electron microscopy of ciliary biopsy or genetic testing.
Explanation: **Explanation:** Infertility is clinically defined as the failure to achieve a clinical pregnancy after **12 months (one year)** or more of regular, unprotected sexual intercourse. This definition is based on the concept of **fecundability**—the probability of achieving pregnancy in a single menstrual cycle. In a healthy couple, the cumulative pregnancy rate is approximately 80-85% within the first year. Therefore, the one-year mark serves as the standard threshold to initiate medical investigations. **Analysis of Options:** * **Option A (One Year):** This is the globally accepted standard by WHO and ACOG. It balances the natural time required for conception with the need for timely medical intervention. * **Option B, C, and D:** These durations (1.5 to 3 years) are considered unnecessarily long. Delaying evaluation for this length of time can lead to a decline in ovarian reserve, especially in older patients, reducing the success rate of future treatments. **High-Yield Clinical Pearls for NEET-PG:** * **Age Exception:** If the female partner is **>35 years old**, the period of unprotected cohabitation required for an infertility diagnosis is reduced to **6 months**. * **Primary vs. Secondary:** Primary infertility refers to a couple who has never achieved pregnancy; Secondary infertility refers to those who have had at least one prior pregnancy (regardless of the outcome). * **Fecundability Rate:** The average monthly chance of conception for a healthy couple is about **20%**. * **Immediate Evaluation:** Investigation should start immediately (without waiting a year) if there is a known history of endometriosis, PCOS, tubal disease, or male factor infertility.
Explanation: The correct answer is **B (Volume >1 mL)** because, according to the **WHO 6th Edition (2021)** and the widely tested **WHO 5th Edition (2010)** guidelines, the lower reference limit for semen volume is **1.5 mL**, not 1 mL. A volume below 1.5 mL is termed hypospermia and may indicate retrograde ejaculation, ductal obstruction, or androgen deficiency. ### Analysis of Incorrect Options: * **A. Sperm count >15 million/mL:** This is a correct WHO criterion. A concentration below this threshold is defined as **oligozoospermia**. * **C. Sperm with normal morphology >4%:** According to **Kruger’s strict criteria**, a sample is considered normal if at least 4% of sperm have ideal head, midpiece, and tail structures. Values below this are termed **teratozoospermia**. * **D. Motility >32%:** The WHO defines normal total motility as ≥40%, but specifically requires **progressive motility (PR) to be ≥32%**. Failure to meet this is termed **asthenozoospermia**. ### High-Yield Clinical Pearls for NEET-PG: * **Azoospermia:** Total absence of spermatozoa in the ejaculate. * **Aspermia:** Complete absence of semen. * **Vitality:** At least **58%** of sperm should be alive (tested via Eosin-Nigrosin stain). * **pH:** Should be **≥7.2** (alkaline). Acidic pH suggests bilateral absence of vas deferens or seminal vesicle obstruction. * **Liquefaction time:** Usually occurs within **15–30 minutes** at room temperature.
Explanation: **Explanation:** The clinical presentation of **6 weeks of amenorrhea** (suggestive of early pregnancy) combined with **acute urinary retention** is a classic triad seen when a pelvic mass becomes "impacted" in the pouch of Douglas, displacing the cervix anteriorly. **1. Why "Impacted Cervical Fibroid" is correct:** In a woman being treated for infertility, a pre-existing cervical or low-lying posterior wall fibroid is common. As the uterus enlarges during early pregnancy (around 6–10 weeks), the fibroid can become incarcerated in the hollow of the sacrum. This pushes the cervix upward and forward against the symphysis pubis, stretching the urethra and compressing the bladder neck, leading to acute urinary retention. **2. Analysis of Incorrect Options:** * **Retroverted Uterus:** While an incarcerated gravid retroverted uterus is a classic cause of urinary retention at 12–14 weeks, it is less likely at only 6 weeks, as the uterus is not yet large enough to fill the pelvic cavity and cause impaction. * **Pelvic Hematocoele:** Usually associated with a ruptured ectopic pregnancy. While it causes pelvic pain and shock, it rarely presents with acute urinary retention as the primary symptom. * **Carcinoma Cervix:** While it can cause urinary symptoms through direct invasion (ureteric obstruction), it typically presents with post-coital bleeding or discharge in older women, not acute retention and amenorrhea in an infertility patient. **Clinical Pearls for NEET-PG:** * **The "12-week rule":** Retroverted gravid uterus typically causes retention at **12–14 weeks** when the fundus gets stuck under the sacral promontory. * **Mechanism:** Retention is due to the **elongation of the urethra** and compression of the bladder neck, not direct pressure on the bladder itself. * **Management:** Immediate catheterization followed by manual correction of the uterine position (if retroverted).
Explanation: **Explanation:** In IVF, the **Long Protocol** (also known as the "Down-regulation protocol") is the most traditional and widely used method for controlled ovarian hyperstimulation. **1. Why Day 21 of the previous cycle is correct:** The primary goal of the long protocol is to achieve complete suppression of the pituitary gland before starting gonadotropins. The GnRH agonist is initiated in the **mid-luteal phase** (typically **Day 21**) of the cycle preceding the IVF stimulation. * **Mechanism:** Initial administration causes a "flare effect" (release of FSH/LH), but continuous administration leads to down-regulation and desensitization of GnRH receptors. This prevents a premature LH surge during the subsequent stimulation phase, ensuring that the follicles grow synchronously and do not ovulate before egg retrieval. **2. Analysis of Incorrect Options:** * **Day 1 of the previous cycle:** Starting this early is unnecessary and would interfere with the previous cycle's physiology without providing additional benefit for down-regulation. * **Day 1 of the IVF cycle:** This is characteristic of the **Short Protocol** (Flare Protocol). Here, the agonist is started on Day 2 to utilize the initial "flare" of endogenous FSH to help recruit follicles. * **Day 21 of the IVF cycle:** By this time, the cycle is usually complete (egg retrieval occurs around Day 14). **3. High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard:** The Long Protocol is considered the gold standard for patients with normal ovarian reserve. * **Down-regulation check:** Successful down-regulation is confirmed by an ultrasound showing a thin endometrium (<5mm) and no ovarian cysts, and serum Estradiol levels <50 pg/mL. * **Antagonist Protocol:** Unlike agonists, GnRH **antagonists** (e.g., Cetrorelix) are started in the *late follicular phase* (Day 6 or when the lead follicle is 14mm) and provide immediate LH suppression.
Explanation: **Explanation:** The management of infertility associated with endometriosis depends on the size of the endometrioma and the severity of the disease. In this case, the patient has a large **(8 cm) endometriotic cyst**, which necessitates surgical intervention before proceeding with fertility treatments. **Why Option B is Correct:** According to standard guidelines (including ESHRE), surgical excision (cystectomy) is recommended for endometriomas **>4 cm** to: 1. Confirm the diagnosis histologically and rule out malignancy. 2. Reduce pelvic pain and improve access to follicles during oocyte retrieval. 3. Prevent complications like cyst rupture or infection during pregnancy/IVF. 4. Improve spontaneous pregnancy rates by reducing the inflammatory environment of the pelvis. **Why Other Options are Incorrect:** * **Option A & D:** IUI and ovulation induction are generally ineffective in the presence of a large endometrioma. The cyst creates a pro-inflammatory microenvironment that impairs oocyte quality, tubal motility, and implantation. Furthermore, an 8 cm mass poses a risk of torsion or rupture during ovarian stimulation. * **Option C:** Medical management with Danazol or GnRH agonists may shrink the lesion temporarily and relieve pain, but it **does not improve fertility** and delays definitive treatment. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** Laparoscopy is the gold standard for diagnosing and staging endometriosis. * **Surgical Choice:** Laparoscopic **cystectomy** is superior to drainage or ablation as it results in lower recurrence rates and higher spontaneous pregnancy rates. * **Ovarian Reserve:** Surgeons must be cautious, as cystectomy can reduce the **Anti-Müllerian Hormone (AMH)** levels due to the removal of healthy ovarian tissue. * **ASRM Staging:** Endometriomas automatically classify the disease as Stage III (Moderate) or Stage IV (Severe).
Reproductive Physiology
Practice Questions
Evaluation of the Infertile Couple
Practice Questions
Male Factor Infertility
Practice Questions
Female Factor Infertility
Practice Questions
Ovulatory Disorders
Practice Questions
Tubal and Peritoneal Factors
Practice Questions
Uterine Factors
Practice Questions
Unexplained Infertility
Practice Questions
Assisted Reproductive Technologies
Practice Questions
Psychological Aspects of Infertility
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free